ADBiotech Co., Ltd. (KOSDAQ:179530)
South Korea · Delayed Price · Currency is KRW 2,010.00
-100.00 (-4.74%)
At close: Aug 11, 2026
ADBiotech Revenue
ADBiotech had revenue of 3.07B KRW in the quarter ending March 31, 2026, a decrease of -11.13%. This brings the company's revenue in the last twelve months to 12.51B, up 1.74% year-over-year. In the year 2025, ADBiotech had annual revenue of 12.90B with 15.81% growth.
Revenue (ttm)
12.51B
Revenue Growth
+1.74%
P/S Ratio
4.33
Revenue / Employee
n/a
Employees
n/a
Market Cap
54.17B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.90B | 1.76B | 15.81% |
| Dec 31, 2024 | 11.14B | 664.30M | 6.34% |
| Dec 31, 2023 | 10.47B | -159.63M | -1.50% |
| Dec 31, 2022 | 10.63B | -1.21B | -10.21% |
| Dec 31, 2021 | 11.84B | 2.02B | 20.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| KoBioLabs | 71.21B |
| Psomagen | 60.70B |
| J2KBIO | 36.82B |
| Naturalendo Tech | 21.69B |
| QuadMedicine | 9.78B |
| TegoScience | 5.83B |
| HLB Pep | 5.52B |
| NovMetaPharma | 1.30B |